Complete restoration of glucocerebrosidase deficiency in Gaucher fibroblasts using a bicistronic MDR retrovirus and a new selection strategy

Human Gene Therapy

Volumn 7, Issue 17, 1996, Pages 2165-2175

  Aran, Josep M ^a   Licht, Thomas ^a,b   Gottesman, Michael M ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISANTRENE; COLCHICINE; COMPLEMENTARY DNA; DOXORUBICIN; ETOPOSIDE; GLUCOSYLCERAMIDASE; GLYCOPROTEIN P; VALSPODAR; VERAPAMIL;

ANIMAL CELL; ARTICLE; CISTRON; CONTROLLED STUDY; ENZYME DEFICIENCY; FIBROBLAST; GAUCHER DISEASE; GENE FUSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; RETROVIRUS; VIRUS RECOMBINANT;

ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0029846013     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.17-2165     Document Type: Article

References (47)

1. AKIYAMA, S-I., GOTTESMAN, M.M., HANOVER, J.A., FITZGERALD, D.J.P., WILLINGHAM, M.C., and PASTAN, I. (1984). Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseodomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin. J. Cell. Physiol. 120, 271-279.
2. AKIYAMA, S-I., SETH, P., PIRKER, R., FITZGERALD, D., GOTTESMAN, M.M., and PASTAN, I. (1985). Potentiation of cytotoxic activity of immunotoxins on cultured human cells. Cancer Res. 45, 1005-1007.
3. ARAN, J.M., GOTTESMAN, M.M., and PASTAN, I. (1994). Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc. Natl. Acad. Sci. USA 91, 3176-3180.
4. ARAN, J.M., GERMANN, U.A., GOTTESMAN, M.M., and PASTAN, I. (1996). Construction and characterization of a selectable multidrug resistance-glucocerebrosidase fusion gene. Cytokines Mol. Ther. 2, 47-57.
5. BARRANGER, J.A., and GINNS, E.I. (1989). Glucosylceramidie lipidoses: Gaucher disease. In The Metabolic Basis of Inherited Disease. C.R. Scriver, A.L., Beaudet, W.S. Sly, and D. Valle, Eds. (McGraw-Hill, New York) vol. 67, pp. 1677-1698.
6. BATES, S.E., ZHAN, Z., DICKSTEIN, B., LEE, J.S., SCALA, S., FOJO, A.T., PAULL, K., and WILSON, W. (1994). Reversal of multidrug resistance. J. Hematother. 3, 219-223.
7. BEUTLER, E. (1992). Gaucher disease: new molecular approaches to diagnosis and treatment. Science 256, 794-799.
8. CARDARELLI, C.O., AKSENTIJEVICH, I., PASTAN, I., and GOTTESMAN, M.M. (1995). Differential effects of P-glycoprotein inhibitors of NIH 3T3 cells transfected with wild-type (G 185) or mutant (V 185) multidrug transporters. Cancer Res. 55, 1086-1091.
9. CENTER, M.S. (1993). Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug. Cytotechnology 12, 109-125.
10. CULLEN, B.R., LOMEDICO, P.T., and JU, G. (1984). Transcriptional interference in avian retroviruses. Implications for the promoter insertion model of leukaemogenesis. Nature 307, 241-245.
11. DANOS, O., and MULLIGAN, R.C. (1988). Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA 85, 6460-6464.
12. EGGERMONT, J., and PROUDFOOT, N.J. (1993). Poly (A) signals and transcriptional pause sites combine to prevent interference between RNA polymerase II promoters. EMBO J. 12, 2539-2548.
13. EMERMAN, M., and TEMIN, H.H. (1984). Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 39, 459-467.
14. EMERMAN, M., and TEMIN, H.H. (1986). Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol. Cell. Biol. 6, 792-800.
15. ERICKSON, A.H., GINNS, E.I., and BARRANGER, J.A. (1985). Biosynthesis of the lysosomal enzyme glucocerebrosidase. J. Biol. Chem. 260, 14319-14324.
16. FINK, J.K., CORRELL, P.H., PERRY, L.K., BRADY, R.O., and KARLSSON, S. (1990). Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease. Proc. Natl. Acad. Sci. USA 87, 2334-2338.
17. FORD, J.M., and HAIT, W.N. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42, 155-199.
18. FORD, J.M., and HAIT, W.N. (1993). Pharmacologic circumvention of multidrug resistance. Cytotechnology 12, 171-212.
19. GINNS, E.I., BRADY, R.O., PIRRUCELLO, S., MOORE, C., SORRELL, S., FURBISH, F.S., MURRAY, G.J., TAGER, J., and BARRANGER, J.A. (1982). Mutations of glucocerebrosidase: Discrimination of neurologic and non-neurologic phenotypes of Gaucher disease. Proc. Natl. Acad. Sci. USA 79, 5607-5610.
20. GOLDSTEIN, L.J. (1995). Clinical reversal of drug resistance. In Current Problems in Cancer. R. F. Ozols, ed. (Mosby-Year Book, Inc. St. Louis, MO) vol. 19, pp. 67-124.
21. GOTTESMAN, M.M., and PASTAN, I. (1991). The multidrug resistance (MDR1) gene as a selectable marker in gene therapy. In Human Gene Transfer. O. Cohen-Haguenauer and M. Boiron, eds. (Colloque INSERM/John Libbey Eurotext Ltd.) vol. 219, pp. 185-191.
22. GOTTESMAN, M.M., and PASTAN, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385-427.
23. GOTTESMAN, M.M., GERMANN, U.A., AKSENTIJEVICH, I., SUGIMOTO, Y., CARDARELLI, C.O., and PASTAN, I. (1994). Gene transfer of drug resistance genes. Implications for cancer therapy. Ann. New York Acad. Sci. 716, 126-139.
24. GOTTESMAN, M.M., HRYCYNA, C.A., SCHOENLEIN, P.V., GERMANN, U.A., and PASTAN, I. (1995). Genetic analysis of the multidrug transporter. Annu. Rev. Genet. 29, 607-649.
25. HABER, M., NORRIS, M.D., KAVALLARIS, M., BELL, D.R., DAVEY, P.A., WHITE, L., and STEWART, B.M. (1989). Atypical multidrug resistance in a therapy-induced drug resistant human leukemia cell line (LALW-2): Resistance to Vinca alkaloids independent of P-glycoprotein. Cancer Res. 49, 5281-5287.
26. HAMADA, H., and TSURUO, T. (1986). Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 83, 7785-7789.
27. HANANIA, E.G., and DEISSEROTH, A.B. (1994). Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther. 1, 21-25.
28. HRYCYNA, C.A., ZHANG, S., RAMACHANDRA, M., NI, B., PASTAN, I., and GOTTESMAN, M.M. (1996). Functional and molecular characterization of the human multidrug transporter. In Multidrug Resistance in Cancer Cells: Cellular, Biochemical, Molecular and Biological Aspects. T. Tsuruo and S. Gupta, eds. (John Wiley and Sons, Ltd. Sussex) (in press).
29. JONSSON, L.M.V., MURRAY, G.J., SORRELL, S.H., STRIJLAND, A., AERTS, J.F.G.M., GINNS, E.I., BARRANGER, J.A., TAGER, J.M., and SCHRAM, A.W. (1987). Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. Eur. J. Biochem. 164, 171-179.
30. KARTNER, N., EVERNDEN-PORELLE, D., BRADLEY, G., and LING, V. (1985). Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 316, 820-823.
31. LEE, J.S., PAULL, K., ALVAREZ, M., HOSE, C., MONKS, A., GREVER, M., FOJO, A.T., and BATES, S.E. (1994). Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46, 627-638.
32. LEVY, M., SPINO, M., and READ, S.E. (1991). Colchicine: A state-of-the-art review. Pharmacotherapy 11, 196-211.
33. + progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Proc. Natl. Acad. Sci. USA 92, 12075-12079.
34. MILLER, A.D., and BUTTIMORE, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6, 2895-2902.
35. MILLER, A.D., and ROSMAN, G.J. (1989). Improved retroviral vectors for gene transfer and expression. BioTechniques 7, 980-990.
36. MILLER, A.D., MILLER, D.G., GARCIA, J.V., and LYNCH, C.M. (1993). Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 217, 581-599.
37. OLSEN, J.C., JOHNSON, L.G., WONG-SUN, M.L., MOORE, K.L., SWANSTROM, R., and BOUCHER, R.C. (1993). Retrovirus-mediated gene transfer to cystic fibrosis airway epithelial cells: effect of selectable marker sequences on long-term expression. Nucleic Acids Res. 21, 663-669.
38. PODDA, S., WARD, M., HIMELSTEIN, A., RICHARDSON, C., DE LA FLOR-WEISS, E., SMITH, L., GOTTESMAN, M., PASTAN, I., and BANK, A. (1992). Transfer and expression of the human multiple drug resistance gene into live mice. Proc. Natl. Acad. Sci. USA 89, 9676-9680.
39. RUSSO, D., MICHELUTTI, A., MIELLI, C., DAMIANI, D., MICHIELI, M.G., CANDONI, A., ZHOU, D.C., MARIE, J.P., ZITTOUN, R., and BACCARANI, M. (1995). MDR-related P 170-glycoprotein modulates cytotoxic activity of homoharringtonine. Leukemia 9, 513-516.
40. SAFA, A.R., STERN, R.K., CHOI, K., AGRESTI, M., TAMAI, I., MEHTA, N.D., and RONINSON, I.B. (1990). Molecular basis of preferential resistance to colchicine in multidrug-resistant cells conferred by Gly-185 → Val-185 substitution in P-glycoprotein. Proc. Natl. Acad. Sci. USA 87, 7225-7229.
41. SORGE, J., KUHL, W., WEST, C., and BEUTLER, E. (1987). Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer. Proc. Natl. Acad. Sci. USA 84, 906-909.
42. SORRENTINO, B.P., BRANDT, S.J., BODINE, D., GOTTESMAN, M., PASTAN, I., CLINE, A., and NIENHUIS, A.W. (1992). Retroviral transfer of the human MDR1 gene permits selection of drug resistant bone marrow cells in vivo. Science 257, 99-103.
43. SUGIMOTO, Y., AKSENTIJEVICH, I., MURRAY, G.J., BRADY, R.O., PASTAN, I., and GOTTESMAN, M.M. (1995). Retroviral coexpression of a multidrug resistance gene (MDR1) and human α-galactosidase A for gene therapy of Fabry disease. Hum. Gene Ther. 6, 905-915.
44. TSURUO, T., and TOMIDA, A. (1995). Multidrug resistance. Anti-Cancer Drugs 6, 213-218.
45. WATANABE, T., TSUGE, H., OH-HARA, T., NAITO, M., and TSURUO, T. (1995). Comparative study on reversal efficiency of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol. 34, 235-241.
46. ZAMAN, G.J.R., FLENS, M.J., VAN LEUSDEN, M.R., DE HAAS, M., MULDER, H.S., LANKELMA, J., PINEDO, H.M., SCHEPER, R.J., BAAS, F., BROXTERMAN, H.J., and BORST, P. (1994). The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA 91, 8822-8826.
47. ZAMORA, J.M., and BECK, W.T. (1986). Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells. Biochem. Pharmacol. 35, 4303-4310.